[Benzodiazepine withdrawal syndrome].
Benzodiazepines (BDZ) are widely prescribed in clinical practice for many pathological conditions, because of their anxiolytic, sedative, myorelaxant and anticonvulsant properties. The effectiveness, specificity and rapidity of action, the few side effects and the virtual absence of toxicity, have contributed to the widespread use of these compounds. In the last decade, however, the attitude towards BDZ has greatly changed, due to growing awareness and concern about dependence liability, withdrawal phenomena, and long-term side effects. Withdrawal symptoms have been singled out and specified in the contest of a well-defined syndrome with foreseeable onset, duration and remission. Psychic and physical symptoms and disorders of sensory perception can be observed. These manifestations can be suppressed by resuming treatment. The symptomatic and developmental aspects of BDZ withdrawal syndrome are discussed, according to the available literature, with particular reference to clinical features of patients suffering from anxiety and mood disorders.
Clinica Psichiatrica II, Università degli Studi di Pisa.
G
G
Perugi
S
S
Michelini
A
A
Petracca
G B
GB
Cassano
D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced* / Q000175:diagnosis; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis; D013997:Time Factors
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines
Sindrome da astinenza da benzodiazepine.